We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+32.87%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$435M
AUM Growth
+$90.3M
Cap. Flow
+$69M
Cap. Flow %
15.87%
Top 10 Hldgs %
46.41%
Holding
58
New
21
Increased
13
Reduced
6
Closed
12

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$16.9M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$15.1M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.7M
4
PTCT icon
PTC Therapeutics
PTCT
+$14M
5
PRTA icon
Prothena Corp
PRTA
+$11.3M

Top Sells

Rank Stock Value
1
KERX
Keryx Biopharmaceuticals Inc
KERX
+$22M
2
CELG
Celgene Corp
CELG
+$20.3M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$15.5M
4
BMY icon
Bristol-Myers Squibb
BMY
+$14.4M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 70.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMAG
51
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-250,000
Closed -$6.07M
MNTA
52
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-27,700
Closed -$490K
KERX
53
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-1,700,000
Closed -$22M
XNPT
54
DELISTED
XENOPORT, INC.
XNPT
– –
-200,000
Closed -$1.15M
DNDN
55
DELISTED
DENDREON CORPORATION
DNDN
– –
-150,000
Closed -$449K
CELG
56
DELISTED
Celgene Corp
CELG
– –
-240,000
Closed -$20.3M
OSIR
57
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
– –
-107,800
Closed -$1.73M
1 2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2014 Portfolio in Review

As of Q1 2014, Cormorant Asset Management held 58 positions worth $435M, up 26% from $345M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cormorant Asset Management deployed $69M of net new capital in Q1 2014, opening 21 new positions and adding to 13 existing holdings. Its largest new stake was Intercept Pharmaceuticals, Inc.: 50,000 shares worth $16.5M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 63% a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $15.5M trimmed.

  • Cormorant Asset Management's largest Q1 2014 buy was Intercept Pharmaceuticals, Inc.: 50,000 shares worth $16.5M.
  • Cormorant Asset Management added most to BioMarin Pharmaceuticals in Q1 2014, an estimated $14.7M increase.
  • Cormorant Asset Management's biggest Q1 2014 reduction was Alnylam Pharmaceuticals, cutting an estimated $15.5M.
  • Cormorant Asset Management fully exited Keryx Biopharmaceuticals Inc in Q1 2014, selling an estimated $22M.
  • Cormorant Asset Management's ten largest holdings make up 46% of its $435M portfolio in Q1 2014.
  • Cormorant Asset Management opened 21 new positions and closed 12 in Q1 2014.
  • Cormorant Asset Management's portfolio value rose 26% quarter-over-quarter to $435M.

Based on Cormorant Asset Management's 13F filing for Q1 2014, filed 15 May 2014.